News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|August 19, 2021

The Gap in the Continuum of Care for Teens and Young Adults

Author(s)Caroline Fenkel, LCSW

Meet the health group that wants to eliminate ER visits during a crisis.

Caroline Fenkel, LCSW, discusses Charlie Health and the gap in continuum of mental health care for teens and young adults.

Caroline Fenkel is co-founder & Chief Clinical Officer at Charlie Health.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Psychiatric Times Experts Weight in on FDA Advisory Decision for PTSD

Psychiatric Times Experts Weigh in on FDA Advisory Decision for PTSD

ByJohn J. Miller, MD,Michael Asbach, DMSc, PA-C, Psych-CAQ,Erin Crown, MHS, PA-C, Psych-CAQ,Leah Kuntz

July 18th 2025

New Africa /Adobestock

Poster at APA Annual Meeting Explores the Use of GLP-1 Agonists for Antipsychotic-Associated Metabolic Issues

ByAmir Meftah, MD,Heidi Anne Duerr, MPH

May 18th 2025

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD

ByMehdi Farokhnia, MD, MPH

June 5th 2024

Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.

Research and Opportunities at the 2024 ASCP Annual Meeting

ByErin Crown, MHS, PA-C, Psych-CAQ

May 30th 2024

Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.

Early Improvement of Symptoms in Bipolar 1 Depression

ByAnita H. Clayton, MD

May 30th 2024

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

December 4-5, 2026

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

FDA Approves First At-Home Brain Stimulation Device for Treatment of Depression

Trontinemab Shows Promise for Treatment of Alzheimer Disease in New Data at CTAD

Colors of the Year for 2026: Which Color Would You Choose for Its Psychological Benefits?

An Update on the Role of Valproate in Bipolar Disorder

Semaglutide Potentially Protective Against Nephrotoxicity Caused by Lithium

© 2025 MJH Life Sciences^®

All rights reserved.